Patents by Inventor Eva Hoess
Eva Hoess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11796540Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: GrantFiled: July 26, 2019Date of Patent: October 24, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Publication number: 20190346439Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: ApplicationFiled: July 26, 2019Publication date: November 14, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Publication number: 20170267736Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with man amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: ApplicationFiled: January 20, 2017Publication date: September 21, 2017Inventors: Friederike HESSE, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
-
Patent number: 9587006Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: GrantFiled: February 4, 2011Date of Patent: March 7, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Friederike Hesse, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
-
Publication number: 20120309679Abstract: Herein is reported a method for producing of a polypeptide conjugated to one poly (ethylene glycol) comprising a) providing a nucleic acid encoding an expression construct comprising in 5? to 3? direction a nucleic acid encoding a polypeptide, and a nucleic acid encoding a trypsin site of SEQ ID NO: 01, b) expressing the nucleic acid of a) in a cell and recovering the expression construct from the cell and/or the cultivation medium, c) providing a target peptide with an amino acid sequence of SEQ ID NO: 02 covalently conjugated to a poly (ethylene glycol) at the C-terminal lysine residue, d) incubating the expression construct and the target peptide with the trypsin mutant D189K, K60E, N143H, E151H, and e) recovering and thereby producing the polypeptide conjugated to one poly (ethylene glycol) from the incubation mixture.Type: ApplicationFiled: February 4, 2011Publication date: December 6, 2012Inventors: Friederike Hesse, Eva Hoess, Stephanie Mueller, Eva Maria Trost-Gross
-
Publication number: 20110112291Abstract: The present invention discloses a composition containing a conjugate comprising two moieties covalently linked by a thiourea linker and thiourea or a derivative thereof in free form. It also relates to a method for stabilizing a conjugate comprising two moieties covalently linked by a thiourea linker is described the method comprising the steps of providing the conjugate, adding thereto thiourea or a derivative thereof in free form and thereby stabilizing the conjugate and to the use of a composition containing a conjugate comprising two moieties covalently linked by a thiourea linker and thiourea or a derivative thereof in free form.Type: ApplicationFiled: November 26, 2008Publication date: May 12, 2011Inventors: Eva Hoess, Rene Blind, Gerhard Fink, Hans-Joachim Kytzia
-
Patent number: 7897404Abstract: The invention relates to a process for the production of a biomolecule-linker conjugate of uniform stochiometry. It especially relates to a conjugate consisting of a biomolecule of a molecular weight between 5 kD and 500 kD and a hydrophilic linker molecule said linker having a molecular weight between 1 and 15 kD and between 4 and 60 charged residues, characterized in that said conjugate comprises at least one biomolecule-linker product of uniform stoichiometry in a pre-selected amount.Type: GrantFiled: August 26, 2001Date of Patent: March 1, 2011Assignee: Roche Diagnostics Operations, Inc.Inventors: Eva Hoess, Herbert Andres, Frederic Donie, Rudolf Vogel, Hans-Peter Josel, Rupert Hermann, Herbert Von Der Eltz
-
Publication number: 20100136519Abstract: The invention concerns a process for the immunological determination of a specific antibody in a fluid sample. The process involves incubating the fluid sample in the presence of a solid phase with two antigens directed against the antibody whose presence is to be determined; the first antigen carries at least one marker group, while the second is either (a) bonded to the solid phase or (b) present in a form in which it can bond with the solid phase, and betrays the presence of the antibody being sought by showing the presence of the marker group in the solid phase and/or in the fluid phase. The proposed process is characterised by the fact that at least one of the two antigens has several epitopic regions which react with the antibody to be determined.Type: ApplicationFiled: October 27, 2009Publication date: June 3, 2010Applicant: Roche Diagnostics GmbHInventors: Ursula-Henrike Wienhues, Cornelia Kruse-Müller, Eva Höss, Elke Faatz, Beatus Ofenloch-Hähnle, Christoph Seidel, Michael Wiedmann
-
Patent number: 7629295Abstract: The invention concerns a method for the immunological determination of a specific antibody in a sample liquid in which the sample liquid is incubated in the presence of a solid phase with two antigens directed against the antibody to be determined of which the first antigen carries at least one marker group and the second antigen is (a) bound to the solid phase or (b) is present in a form capable of binding to the solid phase and the antibody to be determined is detected by determining the marker group in the solid phase or/and in the liquid phase characterized in that at least one of the two antigens contains several epitope regions which react with the antibody to be determined.Type: GrantFiled: July 7, 2003Date of Patent: December 8, 2009Assignee: Roche Diagnostics GmbHInventors: Ursula-Henrike Wienhues, Cornelia Kruse-Müller, Eva Höss, Elke Faatz, Beatus Ofenloch-Hähnle, Christoph Seidel, Michael Wiedmann
-
Publication number: 20090264618Abstract: Disclosed herein are branched linkers of the formula: Zn-Y-Xm Wherein X, Y, Z, m, and n are as defined herein. The branched linkers are useful for producing conjugates that are used in diagnostic or therapeutic methods. Methods of producing the branched linkers are also described.Type: ApplicationFiled: February 13, 2009Publication date: October 22, 2009Inventors: Herbert Andres, Hans-Peter Josel, Eva Hoess, Rupert Herrmann, Herbert Von Der Eltz
-
Patent number: 7476727Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.Type: GrantFiled: February 9, 2007Date of Patent: January 13, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald Sigler, Raymond A. Hui, Ronald Hawley, Eva Hoess, Erasmus J. Huber, John W. Patterson, Salvatore J. Salamone, Allan Dorn
-
Patent number: 7390624Abstract: The invention concerns a process for the production of metal chelate-labelled peptide antigens, peptides obtainable by this process and their use in an immunological method of detection.Type: GrantFiled: February 10, 2003Date of Patent: June 24, 2008Assignee: Roche Diagnostics GmbHInventors: Christoph Seidel, Ursula-Henrike Wienhues, Eva Höss
-
Patent number: 7348423Abstract: A process is disclosed for the production of an antifusogenic peptide by producing a fusion peptide of a length of about 14 to 70 amino acids in a prokaryotic host cell, comprising the steps, under such conditions that inclusion bodies of said fusion peptide are formed, of: (a) expressing in said host cell a nucleic acid encoding said fusion peptide consisting of a first peptide which is an antifusogenic peptide of a length of about 10 to 50 amino acids and a second peptide of a length of about 4 to 30 amino acids, said first peptide being N-terminally linked to said second peptide; (b) cultivating said host cell to produce said inclusion bodies; and (c) recovering said antifusogenic peptide from said inclusion bodies, wherein said recovered antifusogenic peptide consists of said fusion peptide or a peptide comprising the antifusogenic peptide of about 10 to 50 amino acids and which is a fragment cleaved from said fusion peptide. Inclusion bodies of the peptides are disclosed.Type: GrantFiled: October 20, 2004Date of Patent: March 25, 2008Assignee: Hoffmann-La Roche Inc.Inventors: Eva Hoess, Thomas Meier, Gabriele Pestlin, Friedrich Popp, Klaus Reichert, Rainer Schmuck, Bernd Schneidinger, Christoph Seidel, Wilhelm Tischer
-
Publication number: 20080064079Abstract: The invention relates to a mutated trypsin comprising an amino acid substitution both at position K60 and D189, and at least one more amino acid substitution by histidine at position N143 or position E151. Such trypsin mutant has a preferred cleavage site comprising the amino acids Xaa1-Xaa2-His, wherein Xaa1 is L, Y or F and Xaa2 is R or K. The invention also relates to a man-made polypeptide comprising a target peptide and the above cleavage site as well as to a method of producing C-terminally modified target peptides by using this mutated trypsin.Type: ApplicationFiled: February 9, 2007Publication date: March 13, 2008Inventors: Eva Hoess, Frank Bordusa
-
Patent number: 7235675Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.Type: GrantFiled: July 27, 2004Date of Patent: June 26, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald Sigler, Raymond A. Hui, Ronald Hawley, Eva Hoess, Erasmus J. Huber, John W. Patterson, Salvatore J. Salamone, Allan Dorn
-
Publication number: 20070142631Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.Type: ApplicationFiled: February 9, 2007Publication date: June 21, 2007Inventors: Mitali Ghoshal, Gerald Sigler, Raymond Hui, Ronald Hawley, Eva Hoess, Erasmus Huber, John Patterson, Salvatore Salamone, Allan Dorn
-
Publication number: 20050058659Abstract: A process is disclosed for the production of an antifusogenic peptide by producing a fusion peptide of a length of about 14 to 70 amino acids in a prokaryotic host cell, comprising the steps, under such conditions that inclusion bodies of said fusion peptide are formed, of: (a) expressing in said host cell a nucleic acid encoding said fusion peptide consisting of a first peptide which is an antifusogenic peptide of a length of about 10 to 50 amino acids and a second peptide of a length of about 4 to 30 amino acids, said first peptide being N-terminally linked to said second peptide; (b) cultivating said host cell to produce said inclusion bodies; and (c) recovering said antifusogenic peptide from said inclusion bodies, wherein said recovered antifusogenic peptide consists of said fusion peptide or a peptide comprising the antifusogenic peptide of about 10 to 50 amino acids and which is a fragment cleaved from said fusion peptide. Inclusion bodies of the peptides are disclosed.Type: ApplicationFiled: October 20, 2004Publication date: March 17, 2005Inventors: Eva Hoess, Thomas Meier, Gabriele Pestlin, Friedrich Popp, Klaus Reichert, Rainer Schmuck, Bernd Schneidinger, Christoph Seidel, Wilhelm Tischer
-
Patent number: 6858410Abstract: A process is provided for producing an antifusogenic peptide by producing a fusion peptide of from about 14 amino acids up to 70 amino acids in a prokaryotic host cell under conditions in which inclusion bodies are formed. The antifusogenic peptide recovered from the inclusion bodies is a fragment cleaved from the fusion peptide which comprises an antifusogenic peptide.Type: GrantFiled: May 30, 2002Date of Patent: February 22, 2005Assignee: Hoffmann-La Roche Inc.Inventors: Eva Hoess, Thomas Meier, Gabriele Pestlin, Friedrich Popp, Klaus Reichert, Rainer Schmuck, Bernd Schneidinger, Christoph Seidel, Wilhelm Tischer
-
Publication number: 20050009076Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.Type: ApplicationFiled: July 27, 2004Publication date: January 13, 2005Inventors: Mitali Ghoshal, Gerald Sigler, Raymond Hui, Ronald Hawley, Eva Hoess, Erasmus Huber, John Patterson, Salvatore Salamone, Allan Dorn
-
Patent number: 6811998Abstract: The present invention provides a method for the measurement of an analyte in biological samples whereby an uncompetitive inhibitor is coupled to a ligand and utilized in a homogeneous assay. The analyte can be a drug or drug derivative, hormone, polypeptide, or oligonucleotide. The present invention also provides novel compounds, assay reagents and packaged kits useful for performing such measurements.Type: GrantFiled: January 14, 2003Date of Patent: November 2, 2004Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald Sigler, Raymond A. Hui, Ronald Hawley, Eva Hoess, Erasmus J. Huber, John W. Patterson, Salvatore J. Salamone, Allan Dorn